Videos

The US Oncology expert looks back on how far the ovarian cancer treatment space has come, and where it is headed.

The chief executive officer and co-founder of TrialJectory spoke about the online tool and what it offers for patients, providers, and pharmaceutical companies.

The breast cancer expert discussed research recently published in Cancer Medicine, which suggested that delays in adjuvant chemotherapy are associated with worse survival in this patient population.

The MSK expert discussed how telemedicine may change genetic testing and its access for patients.

The expert from Dana-Farber Cancer Institute spoke about the study of pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

The US Oncology expert noted that input of the multidisciplinary board is a great place to air out concerns regarding ovarian cancer treatment.

The MSK expert explained that pre- and post-test education on genetic testing also improved family discussions about their risk.

A study published in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients being seen for cancer-related care due to the COVID-19 pandemic.

The expert oncologist/hematologist spoke with CancerNetwork® about the challenges brought to light by the current pandemic.

Nirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.

The expert from the Dana-Farber Cancer Institute discussed the study findings which assessed the use of pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

The oncologist from the Morrison Cancer Center explained why he believes the general population should not receive multi-gene panel testing.

The researcher from Quest Diagnostics spoke about a recent study which confirmed the benefit of using liquid-based cytology in cotesting for cervical cancer.

The MD Anderson Cancer Center expert discussed the future of acute myeloid leukemia treatment, and how the field is evolving rapidly.

The new guidelines suggest the need to phase out cotesting and cytology, shifting towards primary HPV testing starting at age 25 years.

Interim results from the study suggested that axicabtagene ciloleucel (axi-cel) demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

The US Oncology expert explained that results from 2 trials presented at the 2020 ASCO Virtual Program may change how oncologists choose to treat these patients.

The goal of the initiative is to have cancer screenings that were made in the first half of 2020 and cancelled due to COVID-19 rescheduled to ensure patients are again receiving routine screenings.

The MSK expert explained that pre- and post-test educatin on genetic testing could help patients and providers alike to better understand the results.

The MD Anderson Cancer Center expert discussed next steps in the evaluation of ivosenidib plus venetoclax, with or without azacytidine, in patients with IDH1-mutated acute myeloid leukemia.

The US Oncology expert reported that secondary surgical cytoreduction may not lead to improved outcomes in women platinum-sensitive, recurrent ovarian cancer.

Updated findings further evaluate the effectiveness of various treatments of COVID-19 for patients with cancer and reveal possible racial disparities in enrollment of clinical trials.

Using acupuncture to help manage pain associated with cancer treatment, may offer additional tools to help manage function and quality of life in survivors, according to Jun J. Mao, MD, MSCE.

The CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.

The MSK expert discussed how pre- and post-genetic testing online education made patients more knowledgeable about genetic testing.

The Seattle Cancer Care Alliance expert discusses key takeaways from cohort a of the KEYTRUDA-427 study, evaluating pembrolizumab monotherapy in patients with clear cell renal cell carcinoma.

The expert from the Fox Chase Cancer Center discussed a paper recently published regarding alternative multidisciplinary management options for patients with NSCLC during the COVID-19 pandemic.

The MD Anderson Cancer Center expert spoke about the efficacy of ivosenidib plus venetoclax, with or without azacytidine, in patients with IDH1-mutated acute myeloid leukemia.

The MD Anderson Cancer Center expert discussed further research in delivering online accessible genetic testing.

The board-certified gastroenterologist discussed the lack of screenings being conducted due to the COVID-19 pandemic, and how many physicians have tried to circumvent this issue.